0001209191-17-028615.txt : 20170428 0001209191-17-028615.hdr.sgml : 20170428 20170428134441 ACCESSION NUMBER: 0001209191-17-028615 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20170428 FILED AS OF DATE: 20170428 DATE AS OF CHANGE: 20170428 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Zeltiq Aesthetics Inc CENTRAL INDEX KEY: 0001415336 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] IRS NUMBER: 270119051 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 4410 ROSEWOOD DRIVE CITY: Pleasanton STATE: CA ZIP: 94588 BUSINESS PHONE: (925) 474-2500 MAIL ADDRESS: STREET 1: 4410 ROSEWOOD DRIVE CITY: Pleasanton STATE: CA ZIP: 94588 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Harrison Danika R CENTRAL INDEX KEY: 0001547535 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35318 FILM NUMBER: 17793908 MAIL ADDRESS: STREET 1: C/O ZELTIQ AESTHETICS, INC. STREET 2: 4410 ROSEWOOD DRIVE CITY: PLEASANTON STATE: CA ZIP: 94588 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2017-04-28 1 0001415336 Zeltiq Aesthetics Inc ZLTQ 0001547535 Harrison Danika R C/O ZELTIQ AESTHETICS, INC. 4410 ROSEWOOD DRIVE PLEASANTON CA 94588 0 1 0 0 SVP of Global Marketing Common Stock 2017-04-28 4 D 0 27323 D 0 D Stock Option (right to buy) 40.89 2017-04-28 4 D 0 15562 0.00 D 2027-01-17 Common Stock 15562 0 D Disposed of pursuant to the Agreement and Plan of Merger, dated as of February 13, 2017, by and among Allergan Holdco US, Inc. a wholly owned subsidiary of Allergan plc ("Allergan"), Blizzard Merger Sub, Inc. ("Merger Sub"), and the Issuer (the "Merger Agreement"), as approved by the board of directors of the Issuer (the "Board"), whereby Merger Sub merged with and into the Issuer, with the Issuer continuing on as the surviving corporation (the "Merger"). In connection with the Merger, the Board accelerated and vested in full all equity awards held by the Reporting Person as of immediately prior to the closing of the Merger. Pursuant to the terms of the Merger Agreement, all 27,323 shares were canceled and converted into the right to receive $56.50 per share in cash, without interest and subject to any applicable withholding of taxes. In connection with the Merger, the Board accelerated and vested in full all equity awards held by the Reporting Person as of immediately prior to the closing of the Merger. Pursuant to the terms of the Merger Agreement, all 15,562 shares were canceled and converted into the right to receive $56.50 per share in cash, without interest and subject to any applicable withholding of taxes. /s/ Daniel Gorback, Attorney-in-Fact 2017-04-28